On the morning of May 15, 2025, the Zhangjiang China Medicine Valley Conference Room welcomed a team of evaluation experts led by the Pudong New Area Science and Technology Commission to assess the digital transformation achievements of Shanghai Lishan Biopharmaceutical Co., Ltd. on site. Dr. Zhu Chaoyu, General Manager of Lishan Biotechnology, along with Ms. Guo Yushan, Manager of the Research Project Management Department, Dr. Wang Mengya, Deputy Director of Zhangjiang Live Biopharmaceutical R&D Center, Ms. Song Junmei, Deputy General Manager, Mr. Yang Weikang, Manager of the Production Quality Department, and other team members, participated in the on-site review, which was chaired and reported by Ms. Guo Yushan.

Starting from September 1, 2024, Lishan Biotechnology has completed the upgrade and deployment of the SuperProject pharmaceutical R&D project management system, forming a three in one digital ecosystem of "R&D - finance - office", which enables efficient management of key links such as project planning, task allocation, progress tracking, and resource allocation. This system specifically includes: the introduction of an electronic experimental record management system in the microbiology laboratory to achieve standardized management of experimental processes and records, effectively protecting the safety of core biotechnology and process parameters; Financial management has launched the Kingdee Cloud Accounting System, which enables automated voucher entry and calculation, improves report generation efficiency, enables multitasking parallel processing, and supports real-time cloud and business collaboration of data; In terms of process management, we have completed in-depth customization of the Microsoft Teams platform, optimized cross departmental information sharing, process approval, and task management, created a full process digital collaboration space, and improved internal collaboration efficiency.

During the review process, Dr. Zhu Chaoyu and Dr. Wang Mengya led a team of review experts to visit the laboratory of Lishan Biological Live Biopharmaceutical Research and Development Center, and conducted on-site inspections of the digital level of microbial experimental equipment management. Based on the uniqueness and complexity of the drug research and development field, the company coordinates six core management modules: project schedule, project cost, project quality, project resources, project risk, and project procurement, aiming to create a high-precision and scientifically rigorous drug research and development management platform. After reviewing the details of the transformation and evaluating the relevant materials, Lishan Biotech has successfully completed the digital transformation acceptance work.

Lishan Biotech has always been at the forefront of microbiology, resolutely exploring the future of live biopharmaceuticals. After this digital transformation review meeting, Lishan Biotech will carry out more targeted management and standardized operation of the innovative drug digital platform, continuously growing and transforming in the digital wave.